Novavax, Inc.
NVAX
$6.79
$0.192.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.27% | 9.22% | 25.92% | -30.65% | -15.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.27% | 9.22% | 25.92% | -30.65% | -15.68% |
| Cost of Revenue | -42.06% | -43.57% | -44.42% | -46.92% | -40.72% |
| Gross Profit | 258.71% | 199.72% | 624.50% | 457.19% | 236.80% |
| SG&A Expenses | -49.03% | -44.43% | -28.48% | -25.71% | -9.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.88% | -44.06% | -39.45% | -40.47% | -29.28% |
| Operating Income | 243.72% | 228.18% | 211.92% | 57.97% | 52.62% |
| Income Before Tax | 225.36% | 249.33% | 223.49% | 67.48% | 49.22% |
| Income Tax Expenses | 74.47% | 56.89% | 215.82% | 435.89% | 367.24% |
| Earnings from Continuing Operations | 219.97% | 243.65% | 220.06% | 65.60% | 48.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 219.97% | 243.65% | 220.06% | 65.60% | 48.11% |
| EBIT | 243.72% | 228.18% | 211.92% | 57.97% | 52.62% |
| EBITDA | 285.75% | 269.48% | 240.20% | 64.07% | 57.66% |
| EPS Basic | 198.38% | 198.02% | 198.04% | 77.62% | 65.76% |
| Normalized Basic EPS | 230.98% | 193.35% | 199.26% | 74.18% | 66.85% |
| EPS Diluted | 179.34% | 182.59% | 183.79% | 76.06% | 64.52% |
| Normalized Diluted EPS | 207.29% | 175.98% | 181.47% | 72.55% | 65.58% |
| Average Basic Shares Outstanding | 12.87% | 24.83% | 37.98% | 51.15% | 59.44% |
| Average Diluted Shares Outstanding | 14.92% | 26.69% | 40.90% | 50.02% | 57.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |